[go: up one dir, main page]

MX2016010169A - Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina. - Google Patents

Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.

Info

Publication number
MX2016010169A
MX2016010169A MX2016010169A MX2016010169A MX2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A
Authority
MX
Mexico
Prior art keywords
tablet
formulation
active peptide
peptide compounds
compounds related
Prior art date
Application number
MX2016010169A
Other languages
English (en)
Other versions
MX383378B (es
Inventor
Xu Wei
NOFSINGER Rebecca
LUPTON Lisa
ann johnson Mary
Resende ALLAIN Leonardo
Mark Eickhoff W
B Ikeda Craig
D Brown Chad
J Jr Flanagan Francis
Marota Melanie
B Patel Paresh
XI Hanmi
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53778348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016010169(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016010169A publication Critical patent/MX2016010169A/es
Publication of MX383378B publication Critical patent/MX383378B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención está dirigida a composiciones que comprenden un material extrudido o solución sólida de un compuesto, o una sal del mismo, de fórmula I (API): fórmula I, (ver Fórmula) en donde ``Ra´´ es independientemente H o -F, en una matriz de polímero soluble en agua, la cual comprende adicionalmente un sistema de desintegración que permite que una tableta obtenida del mismo se desintegre rápidamente en el ambiente en el cual el API será liberado.
MX2016010169A 2014-02-05 2015-01-30 Formulación de tableta para compuestos activos de péptido relacionado con el gen de calcitonina. MX383378B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936019P 2014-02-05 2014-02-05
US201462087366P 2014-12-04 2014-12-04
PCT/US2015/013672 WO2015119848A1 (en) 2014-02-05 2015-01-30 Tablet formulation for cgrp-active compounds

Publications (2)

Publication Number Publication Date
MX2016010169A true MX2016010169A (es) 2016-10-07
MX383378B MX383378B (es) 2025-03-13

Family

ID=53778348

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010169A MX383378B (es) 2014-02-05 2015-01-30 Formulación de tableta para compuestos activos de péptido relacionado con el gen de calcitonina.
MX2021006790A MX2021006790A (es) 2014-02-05 2016-08-04 Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006790A MX2021006790A (es) 2014-02-05 2016-08-04 Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.

Country Status (13)

Country Link
US (4) US10117836B2 (es)
EP (1) EP3102564A4 (es)
JP (2) JP6491669B2 (es)
KR (3) KR20230107902A (es)
CN (2) CN105960397B (es)
AU (5) AU2015214502B2 (es)
CA (1) CA2937315A1 (es)
HK (1) HK1232218A1 (es)
IL (1) IL246828B (es)
MX (2) MX383378B (es)
RU (2) RU2696578C1 (es)
SA (1) SA516371613B1 (es)
WO (1) WO2015119848A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501968B (zh) * 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
WO2015119848A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
CN105126111A (zh) * 2015-09-30 2015-12-09 清华大学 提高索拉非尼生物利用度的制剂
SG11201909062WA (en) 2017-03-30 2019-10-30 Merck Patent Gmbh Pharmaceutical formulation
BR112020019396A2 (pt) * 2018-03-25 2021-01-05 Biohaven Pharmaceutical Holding Company Ltd. Rimegepant para distúrbios relacionados a cgrt
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
RU2755571C1 (ru) * 2020-06-09 2021-09-17 Сергей Геннадьевич Каплунов Способ изготовления гравюры на металле
CA3190176A1 (en) 2020-07-29 2022-02-03 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022109077A1 (en) * 2020-11-19 2022-05-27 Biohaven Pharmaceutical Holding Company Ltd. Compositions for improved delivery of cgrp inhibitors
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
JP2024505967A (ja) * 2021-02-02 2024-02-08 イドーシア ファーマシューティカルズ リミテッド （４－メチル－２－［１，２，３］トリアゾール－２－イル－フェニル）－［（ｒ）－３－（３－［１，２，３］トリアゾール－２－イル－ベンジル）－モルホリン－４－イル］－メタノンの結晶形
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
ATE535514T1 (de) 2003-03-14 2011-12-15 Merck Sharp & Dohme Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
AU2004226018B2 (en) 2003-03-14 2009-08-27 Merck Sharp & Dohme Corp. Benzodiazepine spirohydantoin CGRP receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
DE602005020656D1 (de) 2004-09-13 2010-05-27 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
DE102004063755A1 (de) 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
AU2006223236A1 (en) 2005-03-14 2006-09-21 Merck Sharp & Dohme Corp. CGRP receptor antagonists
BRPI0707584A2 (pt) 2006-02-09 2011-05-10 Merck & Co Inc composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica
CN101443323A (zh) 2006-05-09 2009-05-27 默克公司 取代的螺环cgrp受体拮抗剂
US8993588B2 (en) 2007-06-05 2015-03-31 Merck Sharp & Dohme Corp. Carboxamide heterocyclic CGRP receptor antagonists
MX2010003849A (es) 2007-10-18 2010-04-27 Boehringer Ingelheim Int Antagonistas de cgrp.
CA2705599A1 (en) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
WO2009100090A1 (en) * 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
CN102065842A (zh) 2008-04-15 2011-05-18 先灵公司 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
EP2732818B1 (en) * 2009-03-31 2017-05-03 Ligand Pharmaceuticals Inc. A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis
US8765763B2 (en) 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
JP2013542261A (ja) 2010-11-12 2013-11-21 メルク・シャープ・アンド・ドーム・コーポレーション ピペリジノンカルボキサミドインダンｃｇｒｐ受容体アンタゴニスト
TWI501968B (zh) 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
US8895572B2 (en) 2010-12-22 2014-11-25 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide CGRP receptor antagonists
EP2654423B1 (en) 2010-12-22 2016-12-07 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
AU2012225459A1 (en) * 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US9409916B2 (en) 2011-03-18 2016-08-09 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin CGRP receptor antagonists
WO2013036861A1 (en) 2011-09-08 2013-03-14 Codexis, Inc Biocatalysts and methods for the synthesis of substituted lactams
LT2765990T (lt) 2011-10-14 2018-01-25 Array Biopharma, Inc. Solidinė dispersija
RU2667909C2 (ru) 2012-03-14 2018-09-25 Мерк Шарп И Доум Корп. Бисчетвертичные соли алкалоида хинного дерева в качестве асимметрических межфазных катализаторов
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
MX353088B (es) 2012-04-25 2017-12-19 Innovus Pharmaceuticals Inc Composicion de sensibilizacion y metodo de uso.
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
EP2846801B1 (en) 2012-05-09 2017-04-05 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
WO2013169567A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
EP2846798B1 (en) 2012-05-09 2018-04-04 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
RS65500B1 (sr) 2013-03-15 2024-06-28 Tonix Pharma Holdings Ltd Eutektičke formulacije ciklobenzaprin hidrohlorida i manitola
EP3915561A1 (en) 2013-09-16 2021-12-01 Merck Sharp & Dohme Corp. Formulations for cgrp receptor antagonists
WO2015119848A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2015120014A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
US20170189443A1 (en) 2014-02-24 2017-07-06 C. Lowell Parsons Compositions and methods for treatment of diseases and conditions employing oral administration of sodium pentosan polysulfate and other pentosan polysulfate salts
KR102803917B1 (ko) 2014-08-22 2025-05-07 파르마＆ 슈바이츠 게엠베하 루카파립의 고 용량 강도 정제
EA201791662A1 (ru) 2015-01-23 2017-12-29 Грюненталь Гмбх Цебранопадол для лечения от боли субъектов с нарушенной печеночной и/или нарушенной почечной функцией
EA201890578A1 (ru) 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
US20180092899A1 (en) 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190135927A1 (en) 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options
US20190374518A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20190374520A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
US20200383983A1 (en) 2019-04-18 2020-12-10 Allergan Sales, Llc Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
CA3156009A1 (en) 2019-09-25 2021-04-01 Allergan Pharmaceuticals International Limited POLYTHERAPY WITH CGRP ANTAGONISTS
CA3190176A1 (en) 2020-07-29 2022-02-03 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Also Published As

Publication number Publication date
CA2937315A1 (en) 2015-08-13
RU2696578C1 (ru) 2019-08-05
JP6666490B2 (ja) 2020-03-13
IL246828B (en) 2019-05-30
WO2015119848A1 (en) 2015-08-13
KR20160113296A (ko) 2016-09-28
IL246828A0 (en) 2016-08-31
EP3102564A4 (en) 2017-10-18
BR112016017999A8 (pt) 2023-04-11
JP2017505306A (ja) 2017-02-16
JP2019108366A (ja) 2019-07-04
JP6491669B2 (ja) 2019-03-27
US20230248655A1 (en) 2023-08-10
KR102448369B1 (ko) 2022-09-28
MX383378B (es) 2025-03-13
BR112016017999A2 (es) 2017-08-08
EP3102564A1 (en) 2016-12-14
US10117836B2 (en) 2018-11-06
AU2021245229A1 (en) 2021-11-04
CN105960397B (zh) 2020-09-04
AU2025220825A1 (en) 2025-09-11
MX2021006790A (es) 2021-07-15
CN112022818A (zh) 2020-12-04
US20210085612A1 (en) 2021-03-25
KR20220136460A (ko) 2022-10-07
SA516371613B1 (ar) 2021-06-19
US11925709B2 (en) 2024-03-12
AU2023258317A1 (en) 2023-11-16
US20160346214A1 (en) 2016-12-01
AU2015214502A1 (en) 2016-07-21
KR20230107902A (ko) 2023-07-18
CN105960397A (zh) 2016-09-21
HK1232218A1 (zh) 2018-01-05
US20190209478A1 (en) 2019-07-11
AU2019226239B2 (en) 2021-07-08
AU2019226239A1 (en) 2019-09-26
RU2019123406A (ru) 2019-10-03
AU2015214502B2 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
MX2016010169A (es) Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2018006503A (es) Compuesto novedoso de bifenilo o una sal del mismo.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
AR099854A1 (es) Derivados de quinaxolina con acción sobre tirosinquinasas
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
BR112017004798A2 (pt) composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
MX375068B (es) Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.
MX2015016971A (es) Formulacion que comprende un agente hipolipidemico.
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
BR112017012337A2 (pt) Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων
BR112017006918A2 (pt) formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares
BR112015021769A2 (pt) composições farmacêuticas compreendendo um agente ativo
CL2017002229A1 (es) Inhibidores de bace1.
AR107163A1 (es) Inhibidores de quinasa